{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:13:54Z","timestamp":1793128434265,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.annonc.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T11:57:20Z","timestamp":1644839840000},"page":"522-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"V.","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.O.","family":"Iannotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"F\u00e9liz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Lihou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.02.001_bib1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.02.001_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2022.02.001_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.02.001_bib4","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2022.02.001_bib5","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.02.001_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annonc.2022.02.001_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.02.001_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.02.001_bib10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib11","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"issue":"suppl 8","key":"10.1016\/j.annonc.2022.02.001_bib12","doi-asserted-by":"crossref","first-page":"vii319","DOI":"10.1093\/annonc\/mdy283.109","volume":"29","author":"Necchi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.303","article-title":"Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma","volume":"39","author":"Abou-Alfa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2022.02.001_bib19","series-title":"Data on file","year":"2021"},{"key":"10.1016\/j.annonc.2022.02.001_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.02.001_bib21","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2022.02.001_bib22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.02.001_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2022.02.001_bib25","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.02.001_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.annonc.2022.02.001_bib27","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","article-title":"Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","volume":"29","author":"Verstovsek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.02.001_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2\u00a0fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.02.001_bib30","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:08:49Z","timestamp":1760335729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0923753422001107"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}